LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Accueil・Liste d'Actions・Beam Therapeutics Inc

Beam Therapeutics Inc

Ouvert

SecteurSoins de santé

33.23 0.42

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

32.03

Max

33.61

Chiffres clés
By Trading Economics
Revenu	-339M -94M
Ventes	-82M 32M
BPA	-0.91
Marge bénéficiaire	-297.177
Employés	522
EBITDA	-362M -102M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+56.51% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-52M 3B
Ouverture précédente	32.81
Clôture précédente	33.23

Sentiment de l'Actualité

By Acuity

47%

53%

144 / 344 Classement par Healthcare

Beam Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 mai 2026, 22:47 UTC

Résultats

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mai 2026, 20:45 UTC

Résultats

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mai 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mai 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mai 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mai 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mai 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mai 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 mai 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mai 2026, 22:37 UTC

Market Talk

Acquisitions, Fusions, Rachats

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mai 2026, 22:04 UTC

Acquisitions, Fusions, Rachats

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mai 2026, 22:04 UTC

Acquisitions, Fusions, Rachats

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mai 2026, 21:12 UTC

Résultats

Acquisitions, Fusions, Rachats

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mai 2026, 21:00 UTC

Résultats

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mai 2026, 20:57 UTC

Résultats

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mai 2026, 20:55 UTC

Résultats

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 mai 2026, 20:48 UTC

Actions en Tendance

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mai 2026, 20:34 UTC

Résultats

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mai 2026, 20:31 UTC

Résultats

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mai 2026, 20:28 UTC

Résultats

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mai 2026, 20:26 UTC

Résultats

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mai 2026, 20:20 UTC

Résultats

Costco 3Q Membership Fees $1.37B

28 mai 2026, 20:20 UTC

Résultats

Costco 3Q Net Sales $69.15B

28 mai 2026, 20:19 UTC

Résultats

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mai 2026, 20:19 UTC

Résultats

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mai 2026, 20:17 UTC

Résultats

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mai 2026, 20:17 UTC

Résultats

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparaison

Variation de prix

Beam Therapeutics Inc prévision

Objectif de Prix

By TipRanks

56.51% hausse

Prévisions sur 12 Mois

Moyen 49.91 USD 56.51%

Haut 80 USD

Bas 26 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

Achat

Maintien

Vente

Basé sur 12 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

144 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.